UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

2021 ACR guideline reflects changes in RA treatment

Nature reviews. Rheumatology, 2021-09, Vol.17 (9), p.513-514

2021

Volltextzugriff (PDF)

Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis

Rheumatology international, 2018-06, Vol.38 (6), p.935-947

2018

Volltextzugriff (PDF)

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

Annals of the rheumatic diseases, 2012-11, Vol.71 (11), p.1839-1848

2012

Volltextzugriff (PDF)

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

The Lancet (British edition), 2013, Vol.381 (9877), p.1541-1550

2013

Volltextzugriff (PDF)

Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study

Rheumatology (Oxford, England), 2017-12, Vol.56 (12), p.2170-2178

2017

Volltextzugriff (PDF)

Clinical trial development for biosimilars

Seminars in arthritis and rheumatism, 2015-06, Vol.44 (6), p.S2-S8

2015

Volltextzugriff (PDF)

Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007–2017

Rheumatology international, 2020-12, Vol.40 (12), p.2005-2012

2020

Volltextzugriff (PDF)

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

The Lancet (British edition), 2008-03, Vol.371 (9617), p.987-997

2008

Volltextzugriff (PDF)

Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)

Annals of the rheumatic diseases, 2013-02, Vol.72 (2), p.204-210

2013

Volltextzugriff (PDF)

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial

The Lancet (British edition), 2020-07, Vol.396 (10246), p.267-276

2020

Volltextzugriff (PDF)

Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long‐Term Clinical Trial Safety Data in Rheumatoid Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2017-09, Vol.69 (9), p.1751-1761

2017

Volltextzugriff (PDF)

Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis

Acta neuropathologica communications, 2016-04, Vol.4 (1), p.45-45, Article 45

2016

Volltextzugriff (PDF)

Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology

Acta neuropathologica, 2021-06, Vol.141 (6), p.917-927

2021

Volltextzugriff (PDF)

FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension

Arthritis research & therapy, 2019-12, Vol.21 (1), p.281-12, Article 281

2019

Volltextzugriff (PDF)

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study

Annals of the rheumatic diseases, 2019-06, Vol.78 (6), p.754-760

2019

Volltextzugriff (PDF)

Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs

Journal of rheumatology, 2021-08, Vol.48 (8), p.1230-1238

2021

Volltextzugriff (PDF)

Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib

Arthritis research & therapy, 2020-10, Vol.22 (1), p.1-243, Article 243

2020

Volltextzugriff (PDF)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Arthritis research & therapy, 2018-08, Vol.20 (1), p.178-178, Article 178

2018

Volltextzugriff (PDF)

Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes

Therapeutic Advances in Musculoskeletal Disease, 2022, Vol.14, p.1759720X221114101-1759720X221114101

2022

Volltextzugriff (PDF)

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

BMC musculoskeletal disorders, 2011-07, Vol.12 (1), p.153-153, Article 153

2011

Volltextzugriff (PDF)

So behandeln wir Rheumaknoten bei Patienten mit rheumatoider Arthritis in Remission

Zeitschrift für Rheumatologie, 2022-09, Vol.81 (7), p.605-607

2022

Volltextzugriff (PDF)

This is how we treat rheumatoid nodules in patients with rheumatoid arthritis in remission

Zeitschrift für Rheumatologie, 2022-09, Vol.81 (7), p.605

2022

Volltextzugriff (PDF)

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Arthritis research & therapy, 2018-07, Vol.20 (1), p.155-155, Article 155

2018

Volltextzugriff (PDF)

Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials

Arthritis research & therapy, 2021-04, Vol.23 (1), p.119-119, Article 119

2021

Volltextzugriff (PDF)

Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study

Clinical rheumatology, 2019-05, Vol.38 (5), p.1413-1424

2019

Volltextzugriff (PDF)

1 – 25 von 238

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(207)
Mit Volltextzugriff
(189)

Publikationsform

Artikel
(216)
Buchkapitel
(21)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(171)
Life Sciences & Biomedicine
(170)
Rheumatology
(170)
Humans
(122)
Rheumatoid Arthritis
(121)
Male
(74)
Female
(73)
Middle Aged
(66)
Arthritis, Rheumatoid - Drug Therapy
(60)
Treatment Outcome
(54)
Adult
(52)
Patients
(46)
Aged
(45)
Antirheumatic Agents - Therapeutic Use
(36)
Biological And Medical Sciences
(36)
Medical Sciences
(36)
Double-Blind Method
(34)
Medicine
(34)
Severity Of Illness Index
(33)
Medicine & Public Health
(31)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

2021 ACR guideline reflects changes in RA treatment

Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study

Clinical trial development for biosimilars

Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007–2017

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial

Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long‐Term Clinical Trial Safety Data in Rheumatoid Arthritis

Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis

Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology

FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study

Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs

Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

So behandeln wir Rheumaknoten bei Patienten mit rheumatoider Arthritis in Remission

This is how we treat rheumatoid nodules in patients with rheumatoid arthritis in remission

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials

Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study

Suchergebnisse filtern